Observational studyJournal of neuro-oncology2026
Circulating Angiopoietin-1/Angiopoietin-2 ratio may reflect pre- and post-treatment vascular states in Glioblastoma and improve discrimination between tumor recurrence and radiation necrosis.
Observational study in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDistinguishing Glioblastoma (GBM) recurrence from radiation-induced injury, including radiation necrosis (RN), remains a major clinical challenge in neuro-oncology. Because angiogenesis reflects dynamic vascular remodeling, we investigated whether longitudinal assessment of circulating angiogenic mediators, particularly the Angiopoietin-1 to Angiopoietin-2 ratio (Ang-1/Ang-2), could improve discrimination between disease progression and RN.
methodsIn this prospective observational study, 42 patients with newly diagnosed GBM underwent peripheral blood (serum) sampling at index surgery and at reoperation. Circulating angiogenic and inflammatory mediators were quantified using a multiplex bead-based assay. Imaging findings were integrated with histopathological confirmation at reoperation (n = 21).
resultsBaseline Ang-1/Ang-2 ratios were lower (median 3) in patients whose first post-treatment event was RN (n = 11) than in those developing tumor recurrence (median 7, p = 0.028). Higher Ang-1/Ang-2 were associated with reduced RN risk (HR 0.75, p = 0.031). Longitudinally, Ang-1 levels declined following chemoradiotherapy (median change − 9235 pg/mL; p = 0.002), resulting in reduced Ang-1/Ang-2 (p = 0.004). At reoperation, recurrent tumors exhibited higher peripheral Ang-1/Ang-2 than RN (median 2.36 vs. 1.48; p = 0.023). Correlation network analyses of peripheral mediators revealed dense, synchronized signaling in RN and modular network organization with reduced global synchronization in recurrence. The addition of Ang-1/Ang-2 provided a possible incremental explanatory value over advanced imaging alone (ROC 0.94 vs. 0.73; p = 0.055).
conclusionsPeripheral assessment of the Ang-1/Ang-2 ratio may capture a compressed systemic signal reflecting the underlying vascular state beyond the blood-brain barrier. By encoding the balance between vascular stabilization and destabilization within the angiopoietin-Tie2 axis, this ratio provides biologically meaningful information and represents a mechanistically grounded biomarker.
Indexed as
Identifiers
42032362What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.